Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 34, Issue 2, 2007, Pages 280-289

  Wells, George ^a   Li, Tracy ^b   Maxwell, Lara ^a   MacLean, Ross ^b   Tugwell, Peter ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Fatigue; Minimal clinical important difference; Rheumatoid arthritis activity; Sleep quality

Indexed keywords

ABATACEPT; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DELPHI STUDY; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; MINIMALLY CLINICALLY IMPORTANT DIFFERENCES STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SLEEP PATTERN;

ACTIVITIES OF DAILY LIVING; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FATIGUE; HEALTH STATUS; HUMANS; PAIN MEASUREMENT; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS;

EID: 33846952106     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wells GA, Anderson J, Boers M, et al. MCID/Low Disease Activity State Workshop summary recommendations and research agenda. J Rheumatol 2003;30:1115-8.
2. Wells GA, Beaton D, Shea B, et al. Minimal clinically important differences: review of methods. J Rheumatol 2001;28:406-12.
3. Beaton DE, Bombardier C, Katz JN, et al. Looking for important changes/differences in studies of responsiveness. J Rheumatol 2001;28:400-5.
4. Jaeschke R, Singer J, Guyatt GH. Measurement of health status ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-5.
5. Juniper EF, Guyatt GH, Willan A, Griffith L, determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
6. Stratford PW, Binkley JM. Measurement properties of the RM-18: a modified version of the Roland-Morris Disability Scale. Spine 1997;22:2416-21.
7. Stratford PW, Binkley JM, Riddle DL, Guyatt GH. Sensitivity to change of the Roland-Morris Back Pain Questionnaire. 1. Physical Therapy 1998;78:1186-96.
8. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements: an illustration in rheumatology. Arch Intern Med 1993;153:1337-42.
9. Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
10. Bellamy N, Carette S, Ford PM, et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials - results of a consensus development (Delphi) exercise. J Rheumatol 1992;19:451-7.
11. Bellamy N, Anastassiades TP, Buchanan WW, et al. Rheumatoid arthritis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs - results of a consensus development (Delphi) exercise. J Rheumatol 1991;18:1908-5.
12. Bellamy N, Buchanan WW, Esdaile JM, et al. Ankylosing spondylitis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs - results of a consensus development (Delphi) exercise. J Rheumatol 1991;18:1716-22.
13. van Walraven C, Mahon J, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: implications for sample size calcuation. J Clin Epidemiol 1999;52:717-23.
14. Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 1996;3:142-6.
15. Stratford PW, Riddle DL, Binkley JM, Spadoni G, Westaway MD, Padfield B. Using the neck disability index to make decisions concerning individual patients. Physiotherapy Canada 1999;Spring:107-12.
16. Wyrwich KW, Nienaber MA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-78.
17. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting standard error of measurement based criterion for identifying meaningful intra-individual change in health-related quality of life. J Clin Epidemiol 1999;52:861-73.
18. Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease. J Gen Intern Med 2003;18:196-202.
19. Wyrwich KW, Tierney WM, Wolinsky FD. Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire. Qual Life Res 2002;11:1-7.
20. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Felson DT, Anderson JJ, Lange MLM, Wells GA, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core sel measures rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
22. Riddle DL, Stratford PW, Binkley JM. Sensitivity to change of the Roland-Morris Back Pain Questionnaire: 2. Physical Therapy 1998;78:1197-207.
23. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
24. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
25. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of VAS and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004;31:1896-902.
26. Stewart AL, Ware AE. Measuring functioning and well being: The Medical Outcomes Study approach. Durham, NC: Duke University Press; 1992.
27. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.